Matthias Bodenstedt
CIK: 0001920545
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
MoonLake Immunotherapeutics
Discretionary Trading P&L
Holdings
Transaction History (12 total)
- Jun 22, 2026MLTX
MoonLake Immunotherapeutics
Sale(S)Direct39.1K shares at avg. $22.04$862K - Jun 18, 2026MLTX
MoonLake Immunotherapeutics
Sale(S)Direct2.8K shares at avg. $19.60$55K - Jun 17, 2026MLTX
MoonLake Immunotherapeutics
Sale(S)Direct15.1K shares at avg. $19.68$297K - May 11, 2026MLTX
MoonLake Immunotherapeutics
Sale(S)Direct13.7K shares at avg. $20.02$273K - Apr 14, 2026MLTX
MoonLake Immunotherapeutics
Sale(S)Direct2.4K shares at avg. $19.56$47K - Apr 10, 2026MLTX
MoonLake Immunotherapeutics
Sale(S)Direct1.9K shares at avg. $19.51$38K - Apr 9, 2026MLTX
MoonLake Immunotherapeutics
Sale(S)Direct85.9K shares at avg. $18.94$1.6M - Jan 7, 2026MLTX
MoonLake Immunotherapeutics
Award(A)Direct354.3K shares- - Dec 19, 2025MLTX
MoonLake Immunotherapeutics
Conversion(C)Direct294.5K shares- - Dec 19, 2025MLTX
MoonLake Immunotherapeutics
Disposition(D)Direct294.5K shares- - Oct 8, 2025MLTX
MoonLake Immunotherapeutics
Purchase(P)Direct10.9K shares at avg. $9.09$99K - Feb 27, 2025MLTX
MoonLake Immunotherapeutics
Award(A)Direct95.8K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 22, 2026 | MLTX MoonLake Immunotherapeutics | Sale(S) | 39,120 | $22.04 | $862,205 | Direct |
| Jun 18, 2026 | MLTX MoonLake Immunotherapeutics | Sale(S) | 2,794 | $19.60 | $54,762 | Direct |
| Jun 17, 2026 | MLTX MoonLake Immunotherapeutics | Sale(S) | 15,082 | $19.68 | $296,814 | Direct |
| May 11, 2026 | MLTX MoonLake Immunotherapeutics | Sale(S) | 13,653 | $20.02 | $273,333 | Direct |
| Apr 14, 2026 | MLTX MoonLake Immunotherapeutics | Sale(S) | 2,426 | $19.56 | $47,453 | Direct |
| Apr 10, 2026 | MLTX MoonLake Immunotherapeutics | Sale(S) | 1,925 | $19.51 | $37,557 | Direct |
| Apr 9, 2026 | MLTX MoonLake Immunotherapeutics | Sale(S) | 85,870 | $18.94 | $1,626,378 | Direct |
| Jan 7, 2026 | MLTX MoonLake Immunotherapeutics | Award(A) | 354,296 | - | $0 | Direct |
| Dec 19, 2025 | MLTX MoonLake Immunotherapeutics | Conversion(C) | 294,473 | - | - | Direct |
| Dec 19, 2025 | MLTX MoonLake Immunotherapeutics | Disposition(D) | 294,473 | - | - | Direct |
| Oct 8, 2025 | MLTX MoonLake Immunotherapeutics | Purchase(P) | 10,870 | $9.09 | $98,808 | Direct |
| Feb 27, 2025 | MLTX MoonLake Immunotherapeutics | Award(A) | 95,763 | - | - | Direct |
1-12 of 12 transactions
About Bodenstedt Matthias
Bodenstedt Matthias (SEC CIK 0001920545) files insider reports with the SEC as Chief Financial Officer of MoonLake Immunotherapeutics (MLTX).
Signal8 holds 9 ownership filings by Bodenstedt Matthias, all Form 4s, filed between Mar 3, 2025 and Jun 23, 2026. Those filings report 12 transactions, from Feb 27, 2025 to Jun 22, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Bodenstedt Matthias's filings is in ZUG.
Recent filings by Bodenstedt Matthias
- Jun 22, 2026: Open-market sale of MLTX shares (Form 4, code S).
- Jun 18, 2026: Open-market sale of MLTX shares (Form 4, code S).
- Jun 17, 2026: Open-market sale of MLTX shares (Form 4, code S).
- May 11, 2026: Open-market sale of MLTX shares (Form 4, code S).
- Apr 14, 2026: Open-market sale of MLTX shares (Form 4, code S).
Other insiders filing for MoonLake Immunotherapeutics (MLTX)
- Reich Kristian, Chief Scientific Officer
- Santos da Silva Jorge, Chief Executive Officer
- BVF PARTNERS L P/IL, Director
- Phillips Andrew John, Director
- Loy Spike, Director
- Moukheibir Catherine, Director